Insider Ledger
Nektar Therapeutics (NKTR) insider buying and SEC filings
Nektar Therapeutics · CIK 906709
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
- Former names
- INHALE THERAPEUTIC SYSTEMS INC; INHALE THERAPEUTIC SYSTEMS
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$346K
Planned sales (10b5-1)
$2.1M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Aug 18, 2026 | Sale | Jonathan Zalevsky (Chief R&D Officer) sold 186 shares at about $71.98 ($13K). Holdings down 2% to 9,570 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 20, 2026 |
| Aug 18, 2026 | Sale | Howard W. Robin (CEO and Director) sold 418 shares at about $71.98 ($30K). Holdings down 1% to 54,627 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 20, 2026 |
| Jun 30, 2026 | Planned (10b5-1) | Jonathan Zalevsky (Chief R&D Officer) sold 5,681 shares at $70.00 ($398K), marked as a 10b5-1 plan trade. Holdings down 37% to 9,756 shares. | SEC filing Filed Jul 2, 2026 |
| Jun 16–17, 2026 | Planned (10b5-1) | Howard W. Robin (CEO and Director) sold 20,000 shares between Jun 16 and Jun 17 at about $60.75 ($1.2M), marked as a 10b5-1 plan trade. Holdings down 27% to 55,045 shares. | SEC filing Filed Jun 18, 2026 |
| Jun 15, 2026 | Planned (10b5-1) | Jonathan Zalevsky (Chief R&D Officer) sold 5,538 shares at about $60.71 ($336K), marked as a 10b5-1 plan trade. Holdings down 26% to 15,437 shares. | SEC filing Filed Jun 17, 2026 |
| May 19, 2026 | Sale | Jonathan Zalevsky (Chief R&D Officer) sold 199 shares at about $65.51 ($13K). Holdings down 1% to 20,975 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 21, 2026 |
| May 19, 2026 | Sale | Howard W. Robin (CEO and Director) sold 444 shares at about $65.51 ($29K). Holdings down 1% to 75,045 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 21, 2026 |
| Feb 18, 2026 | Sale | Jonathan Zalevsky (Chief R&D Officer) sold 180 shares at about $73.00 ($13K). Holdings down 1% to 21,174 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 20, 2026 |
| Feb 18, 2026 | Sale | Howard W. Robin (CEO and Director) sold 423 shares at about $73.00 ($31K). Holdings down 1% to 75,489 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Feb 20, 2026 |
| Jan 20, 2026 | Planned (10b5-1) | Jonathan Zalevsky (Chief R&D Officer) sold 3,867 shares at about $35.67 ($138K), marked as a 10b5-1 plan trade. Holdings down 15% to 21,354 shares. | SEC filing Filed Jan 22, 2026 |
| Nov 25, 2025 | Sale | Jonathan Zalevsky (Chief R&D Officer) sold 1,157 shares at about $54.28 ($63K). Holdings down 6% to 18,971 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 25, 2025 |
| Nov 25, 2025 | Sale | Mark Andrew Wilson (Chief Legal Officer) sold 630 shares at about $54.28 ($34K). Holdings down 3% to 21,585 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 25, 2025 |
| Nov 25, 2025 | Sale | Howard W. Robin (CEO and Director) sold 2,207 shares at about $54.28 ($120K). Holdings down 4% to 54,245 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 25, 2025 |
12 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow NKTR in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.